📉 The Financial Deep Dive
Metropolis Healthcare Limited reported impressive top-line growth for the third quarter of fiscal year 2026 (ended December 31, 2025). Standalone revenue from operations surged by 61.8% year-on-year to ₹334.78 Cr, a significant leap from ₹206.88 Cr in the prior year's quarter. Consolidated revenue also saw healthy expansion, growing 25.8% YoY to ₹405.91 Cr.
However, the profitability picture presents a mixed bag. On a standalone basis, Profit Before Tax (PBT) increased 15.2% YoY to ₹42.32 Cr, but the PBT margin compressed considerably to 12.6% from 17.7% in Q3 FY25. Exceptional items of ₹7.96 Cr related to new Labour Codes impacted this figure. Consolidated PBT, conversely, grew 35.0% YoY to ₹57.16 Cr, with margins improving to 14.1% from 13.1% YoY, reflecting better operational leverage. Consolidated PAT rose 33.7% YoY to ₹42.09 Cr.
Basic Earnings Per Share (EPS) saw an uptick, with standalone EPS rising to ₹6.18 from ₹5.35 YoY, and consolidated EPS growing to ₹7.99 from ₹6.12 YoY.
🚩 Risks & Outlook
A notable concern for investors is the ongoing tax dispute. Metropolis Healthcare carries a provision of ₹19.64 Cr against an income tax demand of ₹73.06 Cr for assessment years 2014-15 to 2023-24. While some demands have been reduced, the Income Tax Department has filed appeals before the ITAT, Mumbai for AY 2018-19 to AY 2023-24, creating an overhang.
The company also announced a substantial bonus equity share issue in the ratio of 3:1, a move typically aimed at rewarding shareholders and potentially boosting liquidity. Furthermore, the Board approved the sale of its External Quality Assessment Services (EQAS) Division to its wholly-owned subsidiary, Metropolis Quality Solutions Private Limited (MQSPL), for a nominal consideration of up to ₹1.25 crore via a slump sale.
Crucially, the announcement lacked any forward-looking guidance from the management, leaving investors to gauge future performance based on current trends and market conditions. The absence of guidance, coupled with the standalone margin compression and pending tax litigation, warrants cautious monitoring.